
A team of Israeli researchers has expressed concern that surgical scars may be a particularly favorable environment for the development of difficult-to-treat extramedullary disease in multiple myeloma patients.
Extramedullary disease occurs when myeloma cells form tumors outside of a patient’s bones.
The Israeli researchers also suggest that novel anti-myeloma therapies –such as thalidomide (Thalomid), Revlimid (lenalidomide), or Velcade (bortezomib) – and perhaps stem cell transplantation may foster the development of extramedullary disease in scar …
Read the full story »

Results of a recent observational study show that all known molecular subtypes of multiple myeloma are already present at the early, smoldering myeloma and monoclonal gammopathy of undetermined significance stages of the disease.
According to the investigators, these findings indicate that the various molecular subtypes of myeloma, which have different genetic characteristics, are established early in the course of the disease.
The researchers defined the different molecular subtypes of myeloma they investigated based on a method called gene expression profiling. …
Read the full story »

In a recent study conducted in Korea, investigators found that myeloma patients who had higher weights at diagnosis had the longest survival.
Patients who were underweight at diagnosis, on the other hand, had the lowest survival.
The results of the Korean study are similar to those reported by a recent study that examined weight at diagnosis and its impact on survival in U.S. veterans diagnosed with myeloma (see related Beacon news).
In the Korean study, investigators retrospectively analyzed data for …
Read the full story »

Results of several studies investigating Revlimid maintenance therapy for multiple myeloma will be presented at this year’s American Society of Hematology (ASH) annual meeting, which starts later this week.
Today’s article previews the results of the key Revlimid maintenance studies that will be presented at the meeting, drawing on findings published in the meeting abstracts. Some of the study results, it should be noted, will be updated during the presentations at ASH this week and early next week.
The results …
Read the full story »

German researchers recently reported that certain chromosomal abnormalities in patients' myeloma cells are associated with more rapid progression from smoldering myeloma to active, or symptomatic, multiple myeloma.
Specifically, patients in the study who had the chromosomal abnormalities del(17p), t(4;14), and 1q gain, as well as patients with more chromosomes than normal (hyperdiploidy), experienced shorter times until progression to symptomatic myeloma.
Previous studies have shown that hyperdiploidy positively affects outcomes for patients with symptomatic myeloma. In this study, however, the investigators …
Read the full story »

Results of a small Phase 1 study indicate that the investigational drug milatuzumab on its own has limited efficacy in patients with advanced relapsed and refractory multiple myeloma.
The best response the investigators observed in their study was stable disease, which 20 percent of the patients achieved. One patient continued to have stable disease without progression for 17 months.
According to the investigators, these results are in line with those for several other agents in the same class of drugs, …
Read the full story »

Results of a recent international Phase 3 study demonstrate that the addition of Zolinza to Velcade increases response rates and slightly improves progression-free survival in relapsed and refractory myeloma patients compared to treatment with Velcade alone.
Specifically, 56 percent of patients responded to treatment with Zolinza (vorinostat) plus Velcade (bortezomib) compared to 41 percent of patients treated with Velcade plus placebo.
However, despite improvements in responses, the difference in progression-free survival between the two treatment groups …
Read the full story »